Phase II study of intraperitoneal recombinant interleukin-12 (rhIL-12) in patients with peritoneal carcinomatosis (residual disease < 1 cm) associated with ovarian cancer or primary peritoneal carcinoma

Phase II study of intraperitoneal recombinant interleukin-12 (rhIL-12) in patients with peritoneal carcinomatosis (residual disease < 1 cm) associated with ovarian cancer or primary peritoneal carcinoma

<p>Abstract</p> <p>Background</p> <p>Pharmacokinetic advantages of intraperitoneal (IP) rhIL-12, tumor response to IP delivery of other cytokines as well as its potential anti-angiogenic effect provided the rationale for further evaluation of IPrhIL-12 in patients with...

Full description

Bibliographic Details
Main Authors: Garcia Michael E, Seiden Michael V, June Carl, Edwards Robert, Lenzi Renato, Rosenblum Michael, Freedman Ralph S
Format: Article
Language:English
Published: BMC 2007-12-01
Series:Journal of Translational Medicine
Online Access:http://www.translational-medicine.com/content/5/1/66

Similar Items

Similar Items